Clioquinol
Based on 6 publication(s) in Google Scholar
Clioquinol (Iodochlorhydroxyquin) is a topical antifungal agent with anticancer activity. Clioquinol acts as an oral antimicrobial agent for the research of diarrhea and skin infections. Antibiotic. Clioquinol is a chelator that binds to Zn2+ and Cu2+ with a greater affinity than it binds to Ca2+ and Mg2+. Clioquinol freely crosses the blood-brain barrier. Clioquinol can be used for the study of Alzheimer's disease.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.84%
- No. CAS: 130-26-7
- Fòrmula: C9H5ClINO
- Peso molecular:305.50
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antifungal Compound Library
HY-L048
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Antiparasitic Compound library
HY-L082
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Mitochondria-Targeted Compound Library
HY-L089
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Withdrawn Drug Compound Library
HY-L140
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Protection Compound Library
HY-L144
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Mitophagy Compound Library
HY-L180
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Drug Fragment Library
HY-L904
Publications Citing Use of MedChemExpress (MCE) Clioquinol
More- J Transl Med. 2024 Dec 3;22(1):1095. [Abstract]
- Oncogene. 2025 Dec 16. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- Int Immunopharmacol. 2025 Jul 28:160:114984. [Abstract]
- Am J Respir Cell Mol Biol. 2021 Aug;65(2):189-200. [Abstract]
- Front Mol Neurosci. 2022 Jan 12:14:768731. [Abstract]
Ver todos los productos específicos de isoformas Parasite
MoreVer todos los productos específicos de isoformas Antibiotic
More
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BV-2 | EC50 |
>30 μM
Compound: CQ
|
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated NO production after 24 hrs by Griess assay
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated NO production after 24 hrs by Griess assay
|
[PMID: 26473791] |
| Caco-2 | IC50 |
19.29 μg/mL
Compound: Cq
|
Cytotoxicity against human Caco-2 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay
Cytotoxicity against human Caco-2 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay
|
[PMID: 37975824] |
| PBMC | CC50 |
2 μM
Compound: 2, Clioquinol
|
Cytotoxicity against PBMC
Cytotoxicity against PBMC
|
[PMID: 17000109] |
| SH-SY5Y | EC50 |
>1 μM
Compound: Clioquinol
|
Neuroprotective activity against t-BuOOH-induced oxidative stress in human SH-SY5Y cells assessed as inhibition ROS accumulation pre-incubated for 24 hrs before t-BuOOH challnge for 30 mins by DCFH-DA probe based fluorescence assay
Neuroprotective activity against t-BuOOH-induced oxidative stress in human SH-SY5Y cells assessed as inhibition ROS accumulation pre-incubated for 24 hrs before t-BuOOH challnge for 30 mins by DCFH-DA probe based fluorescence assay
|
[PMID: 29420891] |
Clioquinol (0.01-1000 uM; 72 hours) shows anticancer activity against U251, and MV-4-11 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:The MV-4-11, and U-251 cell lines
-
Concentration:0.01, 0.1, 1, 10, 100, 1000 uM
-
Incubation Time:72 hours
-
Result:The IC50s were 32 and 46 μM in U251 and MV-4-11 cells, respectively.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 130-26-7
-
Appearance Solid
-
Peso molecular 305.50
-
Fòrmula C9H5ClINO
-
Color Light yellow to brown
-
SMILES
ClC1=C(C=CC=N2)C2=C(O)C(I)=C1
-
Synonyms
Iodochlorohydroxyquinoline
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
J Transl Med
Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum/Golgi stress and apoptosis. [Abstract]2024 Dec 3;22(1):1095. PMID: 39623468 -
Oncogene
2025 Dec 16. PMID: 41402633 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Int Immunopharmacol
Mitophagy-mtROS axis contributes to anti-tuberculosis-induced liver injury through activation of the cGAS-STING pathway in rat hepatocytes. [Abstract]2025 Jul 28:160:114984. PMID: 40449272 -
Am J Respir Cell Mol Biol
Clioquinol Attenuates Pulmonary Fibrosis through Inactivation of Fibroblasts via Iron Chelation. [Abstract]2021 Aug;65(2):189-200. PMID: 33861690 -
Front Mol Neurosci
The Role of Transient Receptor Potential A1 and G Protein-Coupled Receptor 39 in Zinc-Mediated Acute and Chronic Itch in Mice. [Abstract]2022 Jan 12:14:768731. PMID: 35095413
Solvente y solubilidad
DMSO : ≥ 50 mg/mL (163.67 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (6.81 mM); Suspended solution; Need ultrasonic and warming
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 2 mg/mL (6.55 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (423 KB)
- English - EN (423 KB)
- Français - FR (423 KB)
- Deutsch - DE (423 KB)
- Norwegian - NO (423 KB)
- Español - ES (423 KB)
- Swedish - SV (423 KB)
- Italian - IT (423 KB)
- Korean - KR (423 KB)
- Portuguese - PT (423 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Moe Wehbe, et al. Development of a copper-clioquinol formulation suitable for intravenous use. Drug Deliv Transl Res. 2018 Feb;8(1):239-251. [Content Brief]
[2]. Regland B, et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord. 2001 Nov-Dec;12(6):408-14. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2733 mL | 16.3666 mL | 32.7332 mL | 81.8331 mL |
| 5 mM | 0.6547 mL | 3.2733 mL | 6.5466 mL | 16.3666 mL | |
| 10 mM | 0.3273 mL | 1.6367 mL | 3.2733 mL | 8.1833 mL | |
| 15 mM | 0.2182 mL | 1.0911 mL | 2.1822 mL | 5.4555 mL | |
| 20 mM | 0.1637 mL | 0.8183 mL | 1.6367 mL | 4.0917 mL | |
| 25 mM | 0.1309 mL | 0.6547 mL | 1.3093 mL | 3.2733 mL | |
| 30 mM | 0.1091 mL | 0.5456 mL | 1.0911 mL | 2.7278 mL | |
| 40 mM | 0.0818 mL | 0.4092 mL | 0.8183 mL | 2.0458 mL | |
| 50 mM | 0.0655 mL | 0.3273 mL | 0.6547 mL | 1.6367 mL | |
| 60 mM | 0.0546 mL | 0.2728 mL | 0.5456 mL | 1.3639 mL | |
| 80 mM | 0.0409 mL | 0.2046 mL | 0.4092 mL | 1.0229 mL | |
| 100 mM | 0.0327 mL | 0.1637 mL | 0.3273 mL | 0.8183 mL |
Clioquinol Related Classifications
HY-14603 Related Classifications
Powered by Bioz